Thiamine supplementation to cancer patients

A double edged sword

Laszlo G. Boros, James L. Brandes, Wai Nang Paul Lee, Marta Cascante, Joaquim Puigjaner, Eva Revesz, Tammy M. Bray, William J. Schirmer, W. Scott Melvin

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The objectives of this review are to (a) explain the mechanism by which thiamine (vitamin B1) promotes nucleic acid ribose synthesis and tumor cell proliferation via the nonoxidative transketolase (TK) pathway; (b) estimate the thiamine intake of cancer patients and (c) provide background information and to develop guidelines for alternative treatments with antithiamine transketolase inhibitors in the clinical setting. Clinical and experimental data demonstrate increased thiamine utilization of human tumors and its interference with experimental chemotherapy. Analysis of RNA ribose indicates that glucose carbons contribute to over 90% of ribose synthesis in cultured cervix and pancreatic carcinoma cells and that ribose is synthesized primarily through the thiamine dependent TK pathway (> 70%). Antithiamine compounds significantly inhibit nucleic acid synthesis and tumor cell proliferation in vitro and in vivo in several tumor models. The medical literature reveals little information regarding the role of the thiamine dependent TK reaction in tumor cell ribose production which is a central process in de novo nucleic acid synthesis and the salvage pathways for purines. Consequently, current thiamine administration protocols oversupply thiamine by 200% to 20,000% of the recommended dietary allowance, because it is considered harmless and needed by cancer patients. The thiamine dependent TK pathway is the central avenue which supplies ribose phosphate for nucleic acids in tumors and excessive thiamine supplementation maybe responsible for failed therapeutic attempts to terminate cancer cell proliferation. Limited administration of thiamine and concomitant treatment with transketolase inhibitors is a more rational approach to treat cancer.

Original languageEnglish (US)
Pages (from-to)595-602
Number of pages8
JournalAnticancer Research
Volume18
Issue number1 B
StatePublished - Jan 1998
Externally publishedYes

Fingerprint

Thiamine
Transketolase
Ribose
Neoplasms
Nucleic Acids
Cell Proliferation
Recommended Dietary Allowances
Purines
Cervix Uteri
Therapeutics
Carbon
Phosphates
Guidelines
RNA
Glucose
Drug Therapy

Keywords

  • Chemotherapy resistance
  • Pentose phosphate pathways
  • Ribose synthesis
  • Transketolase reaction
  • Vitamin B

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Boros, L. G., Brandes, J. L., Lee, W. N. P., Cascante, M., Puigjaner, J., Revesz, E., ... Melvin, W. S. (1998). Thiamine supplementation to cancer patients: A double edged sword. Anticancer Research, 18(1 B), 595-602.

Thiamine supplementation to cancer patients : A double edged sword. / Boros, Laszlo G.; Brandes, James L.; Lee, Wai Nang Paul; Cascante, Marta; Puigjaner, Joaquim; Revesz, Eva; Bray, Tammy M.; Schirmer, William J.; Melvin, W. Scott.

In: Anticancer Research, Vol. 18, No. 1 B, 01.1998, p. 595-602.

Research output: Contribution to journalArticle

Boros, LG, Brandes, JL, Lee, WNP, Cascante, M, Puigjaner, J, Revesz, E, Bray, TM, Schirmer, WJ & Melvin, WS 1998, 'Thiamine supplementation to cancer patients: A double edged sword', Anticancer Research, vol. 18, no. 1 B, pp. 595-602.
Boros LG, Brandes JL, Lee WNP, Cascante M, Puigjaner J, Revesz E et al. Thiamine supplementation to cancer patients: A double edged sword. Anticancer Research. 1998 Jan;18(1 B):595-602.
Boros, Laszlo G. ; Brandes, James L. ; Lee, Wai Nang Paul ; Cascante, Marta ; Puigjaner, Joaquim ; Revesz, Eva ; Bray, Tammy M. ; Schirmer, William J. ; Melvin, W. Scott. / Thiamine supplementation to cancer patients : A double edged sword. In: Anticancer Research. 1998 ; Vol. 18, No. 1 B. pp. 595-602.
@article{91df542d848044e6ba3103b1b9814ef6,
title = "Thiamine supplementation to cancer patients: A double edged sword",
abstract = "The objectives of this review are to (a) explain the mechanism by which thiamine (vitamin B1) promotes nucleic acid ribose synthesis and tumor cell proliferation via the nonoxidative transketolase (TK) pathway; (b) estimate the thiamine intake of cancer patients and (c) provide background information and to develop guidelines for alternative treatments with antithiamine transketolase inhibitors in the clinical setting. Clinical and experimental data demonstrate increased thiamine utilization of human tumors and its interference with experimental chemotherapy. Analysis of RNA ribose indicates that glucose carbons contribute to over 90{\%} of ribose synthesis in cultured cervix and pancreatic carcinoma cells and that ribose is synthesized primarily through the thiamine dependent TK pathway (> 70{\%}). Antithiamine compounds significantly inhibit nucleic acid synthesis and tumor cell proliferation in vitro and in vivo in several tumor models. The medical literature reveals little information regarding the role of the thiamine dependent TK reaction in tumor cell ribose production which is a central process in de novo nucleic acid synthesis and the salvage pathways for purines. Consequently, current thiamine administration protocols oversupply thiamine by 200{\%} to 20,000{\%} of the recommended dietary allowance, because it is considered harmless and needed by cancer patients. The thiamine dependent TK pathway is the central avenue which supplies ribose phosphate for nucleic acids in tumors and excessive thiamine supplementation maybe responsible for failed therapeutic attempts to terminate cancer cell proliferation. Limited administration of thiamine and concomitant treatment with transketolase inhibitors is a more rational approach to treat cancer.",
keywords = "Chemotherapy resistance, Pentose phosphate pathways, Ribose synthesis, Transketolase reaction, Vitamin B",
author = "Boros, {Laszlo G.} and Brandes, {James L.} and Lee, {Wai Nang Paul} and Marta Cascante and Joaquim Puigjaner and Eva Revesz and Bray, {Tammy M.} and Schirmer, {William J.} and Melvin, {W. Scott}",
year = "1998",
month = "1",
language = "English (US)",
volume = "18",
pages = "595--602",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - Thiamine supplementation to cancer patients

T2 - A double edged sword

AU - Boros, Laszlo G.

AU - Brandes, James L.

AU - Lee, Wai Nang Paul

AU - Cascante, Marta

AU - Puigjaner, Joaquim

AU - Revesz, Eva

AU - Bray, Tammy M.

AU - Schirmer, William J.

AU - Melvin, W. Scott

PY - 1998/1

Y1 - 1998/1

N2 - The objectives of this review are to (a) explain the mechanism by which thiamine (vitamin B1) promotes nucleic acid ribose synthesis and tumor cell proliferation via the nonoxidative transketolase (TK) pathway; (b) estimate the thiamine intake of cancer patients and (c) provide background information and to develop guidelines for alternative treatments with antithiamine transketolase inhibitors in the clinical setting. Clinical and experimental data demonstrate increased thiamine utilization of human tumors and its interference with experimental chemotherapy. Analysis of RNA ribose indicates that glucose carbons contribute to over 90% of ribose synthesis in cultured cervix and pancreatic carcinoma cells and that ribose is synthesized primarily through the thiamine dependent TK pathway (> 70%). Antithiamine compounds significantly inhibit nucleic acid synthesis and tumor cell proliferation in vitro and in vivo in several tumor models. The medical literature reveals little information regarding the role of the thiamine dependent TK reaction in tumor cell ribose production which is a central process in de novo nucleic acid synthesis and the salvage pathways for purines. Consequently, current thiamine administration protocols oversupply thiamine by 200% to 20,000% of the recommended dietary allowance, because it is considered harmless and needed by cancer patients. The thiamine dependent TK pathway is the central avenue which supplies ribose phosphate for nucleic acids in tumors and excessive thiamine supplementation maybe responsible for failed therapeutic attempts to terminate cancer cell proliferation. Limited administration of thiamine and concomitant treatment with transketolase inhibitors is a more rational approach to treat cancer.

AB - The objectives of this review are to (a) explain the mechanism by which thiamine (vitamin B1) promotes nucleic acid ribose synthesis and tumor cell proliferation via the nonoxidative transketolase (TK) pathway; (b) estimate the thiamine intake of cancer patients and (c) provide background information and to develop guidelines for alternative treatments with antithiamine transketolase inhibitors in the clinical setting. Clinical and experimental data demonstrate increased thiamine utilization of human tumors and its interference with experimental chemotherapy. Analysis of RNA ribose indicates that glucose carbons contribute to over 90% of ribose synthesis in cultured cervix and pancreatic carcinoma cells and that ribose is synthesized primarily through the thiamine dependent TK pathway (> 70%). Antithiamine compounds significantly inhibit nucleic acid synthesis and tumor cell proliferation in vitro and in vivo in several tumor models. The medical literature reveals little information regarding the role of the thiamine dependent TK reaction in tumor cell ribose production which is a central process in de novo nucleic acid synthesis and the salvage pathways for purines. Consequently, current thiamine administration protocols oversupply thiamine by 200% to 20,000% of the recommended dietary allowance, because it is considered harmless and needed by cancer patients. The thiamine dependent TK pathway is the central avenue which supplies ribose phosphate for nucleic acids in tumors and excessive thiamine supplementation maybe responsible for failed therapeutic attempts to terminate cancer cell proliferation. Limited administration of thiamine and concomitant treatment with transketolase inhibitors is a more rational approach to treat cancer.

KW - Chemotherapy resistance

KW - Pentose phosphate pathways

KW - Ribose synthesis

KW - Transketolase reaction

KW - Vitamin B

UR - http://www.scopus.com/inward/record.url?scp=0031900422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031900422&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 595

EP - 602

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -